FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617381402> ?p ?o ?g. }

• W2617381402 abstract "Abstract Loss of TP53 and RB1 function have both been linked to poor response to DNA damaging drugs in breast cancer patients. We inactivated TP53 and/or RB1 by siRNA mediated knockdown in breast cancer cell lines varying with respect to ER/PgR and Her-2 status as well as TP53 and RB1 mutation status (MCF-7, T47D, HTB-122 and CRL2324) and determined effects on cell cycle arrest, apoptosis and senescence with or without concomitant treatment with doxorubicin. In T47D cells, we found the cell cycle phase distribution to be altered when inactivating TP53 ( P =0.0003) or TP53 and RB1 concomitantly ( P ≤0.001). No similar changes were observed in MCF-7, HTB-122 or CRL2324 cells. While no significant change was observed for the CRL2324 cells upon doxorubicin treatment, MCF-7, T47D as well as HTB-122 cells responded to knockdown of TP53 and RB1 in concert, with a decrease in the fraction of cells in G1/G0-phase ( P =0.042, 0.021 and 0.027, respectively). Inactivation of TP53 and/or RB1 caused no change in induction of apoptosis. Upon doxorubicin treatment, inactivation of TP53 or RB1 separately caused no induction of apoptosis in MCF-7 and HTB-122 cells; however, concomitant inactivation leads to a slightly reduced activation of apoptosis. Interestingly, upon doxorubicin treatment, concomitant inactivation of TP53 and RB1 caused a decrease in senescence in MCF-7 cells ( P =0.027). Comparing the effects of concomitant knockdown on apoptosis and senescence, we observed a strong interaction ( P =0.001). We found concomitant inactivation of TP53 and RB1 to affect various routes of response to doxorubicin treatment in breast cancer cells." @default.
• W2617381402 created "2017-06-05" @default.
• W2617381402 creator A5035837487 @default.
• W2617381402 creator A5040470817 @default.
• W2617381402 creator A5064953838 @default.
• W2617381402 date "2017-05-22" @default.
• W2617381402 modified "2023-10-15" @default.
• W2617381402 title "Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines" @default.
• W2617381402 cites W1545084887 @default.
• W2617381402 cites W1709607181 @default.
• W2617381402 cites W1933858499 @default.
• W2617381402 cites W1982547197 @default.
• W2617381402 cites W1985527634 @default.
• W2617381402 cites W1988936955 @default.
• W2617381402 cites W1990161819 @default.
• W2617381402 cites W1993804965 @default.
• W2617381402 cites W1997130060 @default.
• W2617381402 cites W2008030091 @default.
• W2617381402 cites W2010183849 @default.
• W2617381402 cites W2017168362 @default.
• W2617381402 cites W2028361915 @default.
• W2617381402 cites W2051025382 @default.
• W2617381402 cites W2052878543 @default.
• W2617381402 cites W2063669247 @default.
• W2617381402 cites W2066122607 @default.
• W2617381402 cites W2071333117 @default.
• W2617381402 cites W2071906362 @default.
• W2617381402 cites W2077506183 @default.
• W2617381402 cites W2079941948 @default.
• W2617381402 cites W2080211249 @default.
• W2617381402 cites W2099186537 @default.
• W2617381402 cites W2107633226 @default.
• W2617381402 cites W2113633750 @default.
• W2617381402 cites W2113895281 @default.
• W2617381402 cites W2114372657 @default.
• W2617381402 cites W2118833232 @default.
• W2617381402 cites W2120678034 @default.
• W2617381402 cites W2124544785 @default.
• W2617381402 cites W2142588358 @default.
• W2617381402 cites W2142739240 @default.
• W2617381402 cites W2149434326 @default.
• W2617381402 cites W2150183586 @default.
• W2617381402 cites W2150451425 @default.
• W2617381402 cites W2150618856 @default.
• W2617381402 cites W2154799239 @default.
• W2617381402 cites W4376848528 @default.
• W2617381402 doi "https://doi.org/10.1038/cddiscovery.2017.26" @default.
• W2617381402 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5439126" @default.
• W2617381402 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28580174" @default.
• W2617381402 hasPublicationYear "2017" @default.
• W2617381402 type Work @default.
• W2617381402 sameAs 2617381402 @default.
• W2617381402 citedByCount "19" @default.
• W2617381402 countsByYear W26173814022017 @default.
• W2617381402 countsByYear W26173814022018 @default.
• W2617381402 countsByYear W26173814022019 @default.
• W2617381402 countsByYear W26173814022020 @default.
• W2617381402 countsByYear W26173814022021 @default.
• W2617381402 countsByYear W26173814022022 @default.
• W2617381402 countsByYear W26173814022023 @default.
• W2617381402 crossrefType "journal-article" @default.
• W2617381402 hasAuthorship W2617381402A5035837487 @default.
• W2617381402 hasAuthorship W2617381402A5040470817 @default.
• W2617381402 hasAuthorship W2617381402A5064953838 @default.
• W2617381402 hasBestOaLocation W26173814021 @default.
• W2617381402 hasConcept C105696609 @default.
• W2617381402 hasConcept C109541995 @default.
• W2617381402 hasConcept C121608353 @default.
• W2617381402 hasConcept C126322002 @default.
• W2617381402 hasConcept C143425029 @default.
• W2617381402 hasConcept C173396325 @default.
• W2617381402 hasConcept C185592680 @default.
• W2617381402 hasConcept C190283241 @default.
• W2617381402 hasConcept C2776694085 @default.
• W2617381402 hasConcept C2779384505 @default.
• W2617381402 hasConcept C2781303535 @default.
• W2617381402 hasConcept C29537977 @default.
• W2617381402 hasConcept C2994423619 @default.
• W2617381402 hasConcept C31573885 @default.
• W2617381402 hasConcept C502942594 @default.
• W2617381402 hasConcept C522857546 @default.
• W2617381402 hasConcept C552990157 @default.
• W2617381402 hasConcept C55493867 @default.
• W2617381402 hasConcept C71924100 @default.
• W2617381402 hasConcept C86803240 @default.
• W2617381402 hasConcept C95444343 @default.
• W2617381402 hasConcept C96232424 @default.
• W2617381402 hasConceptScore W2617381402C105696609 @default.
• W2617381402 hasConceptScore W2617381402C109541995 @default.
• W2617381402 hasConceptScore W2617381402C121608353 @default.
• W2617381402 hasConceptScore W2617381402C126322002 @default.
• W2617381402 hasConceptScore W2617381402C143425029 @default.
• W2617381402 hasConceptScore W2617381402C173396325 @default.
• W2617381402 hasConceptScore W2617381402C185592680 @default.
• W2617381402 hasConceptScore W2617381402C190283241 @default.
• W2617381402 hasConceptScore W2617381402C2776694085 @default.
• W2617381402 hasConceptScore W2617381402C2779384505 @default.
• W2617381402 hasConceptScore W2617381402C2781303535 @default.
• W2617381402 hasConceptScore W2617381402C29537977 @default.
• W2617381402 hasConceptScore W2617381402C2994423619 @default.

• next